Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-10T20:43:10.504Z Has data issue: false hasContentIssue false

Chapter 19 - The Use of Botulinum Toxin in Spasticity

Published online by Cambridge University Press:  02 November 2023

Daniel Truong
Affiliation:
University of California, Riverside
Dirk Dressler
Affiliation:
Hannover Medical School
Mark Hallett
Affiliation:
National Institutes of Health (NIH)
Christopher Zachary
Affiliation:
University of California, Irvine
Mayank Pathak
Affiliation:
Truong Neuroscience Institute
Get access

Summary

Spasticity is part of the upper motor neuron syndrome produced by conditions such as stroke, multiple sclerosis, traumatic brain injury, spinal cord injury or cerebral palsy that affect upper motor neurons or their efferent pathways in the brain or spinal cord. It is characterized by increased muscle tone, exaggerated tendon reflexes, repetitive stretch reflex discharges (clonus) and abnormal spastic posturing. Late sequelae may include contracture, pain, fibrosis and muscle atrophy. The most common pattern of spasticity in the upper limb involves flexion of the fingers, wrist and elbow, adduction with internal rotation at the shoulder and sometimes thumb curling across the palm or fist. The most common pattern of spasticity in the lower limb involves extension at the knee, plantarflexion at the ankle and sometimes inversion of the foot.

Chemodenervation by intramuscular injection of botulinum toxin can reduce spastic muscle tone, normalize limb posture, ameliorate pain, modestly improve motor function and prevent contractures. This chapter uses anatomical illustrations to depict the muscles involved in common patterns of spastic posturing, using a “clinician’s eye” view to demonstrate approaches to injection points, discusses guidance techniques such as electromyography and tabulates dose ranges of the common toxin preparations for specific muscles.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barnes, M, Schnitzler, A, Medeiros, L et al. (2010). Efficacy and safety of NT 201 for upper limb spasticity of various etiologies – a randomized parallel-group study. Acta Neurol Scand, 122 , 295302.CrossRefGoogle ScholarPubMed
Brashear, A, Mcafee, AL, Kuhn, ER, Ambrosius, WT (2003). Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil, 84, 1037.CrossRefGoogle ScholarPubMed
Brashear, A, Mcafee, AL, Kuhn, ER, Fyffe, J (2004). Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil, 85 , 7059.CrossRefGoogle ScholarPubMed
Childers, MK (2003). The importance of electromyographic guidance and electrical stimulation for injection of botulinum toxin. Phys Med Rehabil Clin N Am, 14, 78192.CrossRefGoogle ScholarPubMed
Dastipour, K, Chen, JJ, Walker, HW, Lee, MY (2015). Systematic literature review of abobotulinumtoxinA in clinical treials for adult upper limb spasticity. Am J Phys Med Rehabil, 94, 22938.CrossRefGoogle Scholar
Dong, Y, Wu, T, Hu, X, Wang, T (2017). Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis. Eur J Phys Rehabil Med, 53, 25667.Google Scholar
Francisco, GE (2004). Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil, 83 , S30–7.CrossRefGoogle ScholarPubMed
Gracies, JM, Esquenazi, A, Brashear, A et al.; International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group. (2017). Efficacy and safety of abobotulinumtoxinA in spastic lower limb: randomized trial and extension. Neurology, 22, 224553.CrossRefGoogle Scholar
Gupta, AD, Visvanathan, R, Cameron, I et al. (2019). Efficacy of botulinum toxin in modifying spasticity to improve walking and quality of life in post-stroke lower limb spasticitya randomized double-blind placebo controlled study. BMC Neurol, 19, 96.Google Scholar
Hesse, S, Hahnke, MR, Luecke, D et al. (1995). Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett, 201, 3740.CrossRefGoogle ScholarPubMed
Hyman, N, Barnes, M, Bhakta, B et al. (2000). Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry, 68, 70712.CrossRefGoogle ScholarPubMed
Kaňovský, P, Slawekj, J, Denes, Z et al. (2009). Efficacy and safety of botulinum neurotoxin NT201 in poststroke upper lib spasticity. Clin Neuropharm, 32, 25965.CrossRefGoogle Scholar
Lance, JW (1981). Disordered muscle tone and movement. Clin Exp Neurol, 18, 2735.Google ScholarPubMed
Mayer, NH, Esquenazi, A, Childers, MK (2002). Common patterns of clinical motor dysfunction. In Mayer, NH, Simpson, DM (eds.) Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. New York: WE MOVE, pp. 1626.Google Scholar
Raj, PPE. (2004) Treatment algorithm overview: BoNT therapy for pain, appendix A. Pain Practice, 4, S60–4.CrossRefGoogle Scholar
Santamato, A, Ranieri, M, Solfrizzi, V et al. (2016). High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective? Expert Opin Drug Metab Toxicol, 12, 843–6.CrossRefGoogle ScholarPubMed
Santamato, A, Cinone, N, Panza, F et al. (2019). Botulinum toxin type A for the treatment of lower limb spasticity after stroke. Drugs, 79, 143–60.Google Scholar
Suputtitada, A, Suwanwela, NC (2005). The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil, 27 , 176–84.CrossRefGoogle ScholarPubMed
WE MOVE Spasticity Study Group. (2005a). BTX-A adult dosing guidelines. WE MOVE. www.mdvu.org/library/dosingtables/btxa_adg.htmlGoogle Scholar
WE MOVE Spasticity Study Group. (2005b). BTX-B adult dosing guidelines. WE MOVE. www.mdvu.org/library/dosingtables/btxb_adg.htmlGoogle Scholar
Wissel, J, Ward, A, Erztgaard, P et al. (2009). European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med, 41, 1325.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×